Nu Skin Enterprises, Inc. Q3 2026 Earnings Recap

Nu Skin shares fell 8.9% after earnings, despite revenue and adjusted EPS landing within the company’s guidance range. The likely disappointment was continued pressure in the core business: customer and sales metrics remain under pressure, and management’s outlook for Q4 relies on anticipated sequential revenue growth rather than describing a recovery already underway.

Key Takeaways

• Q3 revenue was $311 million and adjusted EPS was $0.10, both within guidance.
• Management said overall customer and sales metrics remain under pressure, while focusing on rebuilding sales-channel engagement and productivity.
• Prysm iO has been placed in approximately 41,000 devices, with 4.5 million scans completed. After the app’s 2.0 update, scan-to-purchase conversion more than doubled to 10%.
• LifePak sales grew nearly 3% year to date; the company also cited strong year-over-year revenue growth at its Rhyz manufacturing platform, without providing a figure.
• For Q4, management anticipates sequential revenue growth. Nu Skin is preparing for India’s formal launch in the first half of 2027 and says its operating changes are intended to improve efficiency and profitability over time.